James Patrick Nelli Jr. - Sep 13, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: President
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Sep 13, 2021
Transactions value $: -$1,329,049
Form type: 4
Date filed: 9/15/2021, 05:16 PM
Previous filing: Sep 3, 2021
Next filing: Dec 7, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$196K	+18.2K	+13.94%	$10.80	149K	Sep 13, 2021	Direct
transaction	HCAT	Common Stock	Options Exercise	$83.7K	+7.81K	+5.25%	$10.72	156K	Sep 13, 2021	Direct
transaction	HCAT	Common Stock	Sale	-$1.36M	-24.8K	-15.82%	$54.83	132K	Sep 13, 2021	Direct	F1, F2
transaction	HCAT	Common Stock	Sale	-$252K	-4.63K	-3.51%	$54.44	127K	Sep 13, 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-18.2K	-25.83%	$0.00	52.2K	Sep 13, 2021	Common Stock	18.2K	$10.80	Direct	F4
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-7.81K	-65.87%	$0.00	4.05K	Sep 13, 2021	Common Stock	7.81K	$10.72	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 10, 2021 in accordance with Rule 10b5-1.
F2	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.32 to $55.31, inclusive.
F3	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.32 to $56.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth Footnotes (2) and (3).
F4	25% of the 215,741 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.
F5	25% of the 80,977 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on October 26, 2021.